Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience

Rendi‐Wagner, Pamela; Kundi, Michael; Stemberger, H; Wiedermann, G; Holzmann, Heidemarie; Hofer, Michaël; Wiesinger, Karin; Kollaritsch, Herwig

doi:10.1016/s0264-410x(00)00410-2

Cited by 98 publications

(54 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24,31 In the present study, the percentage of good responder in female was higher than male, and the anti-HBs GMTs in female was higher than male. When the respective groups were compared, there was no significant difference.…”

Section: Discussioncontrasting

confidence: 39%

The response of hepatitis B vaccination on seronegative adults with different vaccination schedules

Yao

Chen

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

y These authors equally contributed to this work. Keywords: Hepatitis B vaccine, immunization, adults, ChinaThe purpose of this study was to compare the response of hepatitis B vaccination with different vaccination schedules among seronegative adults, and to provide suitable vaccination schedules for floating and fixed population. The study included adults aged 20 to 39 y without prior history of vaccination with hepatitis B vaccine. The serum samples were collected and tested for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) levels. Out of all, 686 adults who were negative for anti-HBs, anti-HBc and HBsAg were vaccinated with 10 ug hepatitis B vaccine at 0, 1 and 3, 6 or 12 month schedules, and their antibody titers were monitored. The rates of completion of the vaccination in floating and fixed population were 90.4% and 94.1% respectively (p D 0.061). The anti-HBs positive rates in adults vaccinated at 0, 1 and 3 ,6 or12 month were 83.9%, 88.2% and 94.2% respectively (P D 0.0003). The corresponding geometric mean titers (GMTs) were 61.19 (95%CI:47.10-81.23) mIU/mL, 214.04(95%CI:157.14-291.61) mIU/mL and 345.78(95%CI:251.25-475.77) mIU/mL, respectively ( P < 0.0001). Vaccination of hepatitis B with both 0-1-6 and 0-1-12 month schedules in adults result in better level of immune responses. Also, a longer vaccination schedule (0-1-12 month) may be more suitable for floating population and 0-1-6 month schedule is recommended for the fixed population.

show abstract

Section: Discussioncontrasting

confidence: 39%

The response of hepatitis B vaccination on seronegative adults with different vaccination schedules

Yao

Chen

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…[19][20][21][22][23][24][25][26][27] Studies suggest that higher HBsAg formulation of HBV vaccines may be associated with faster seroconversion rates and higher peak antibody levels, as well as improved sero-protection rates in populations difficult to immunize. [28][29][30] Since 2012, Chinese authorities abolished 5 mg HBV vaccines and defined 10 mg HBV vaccines for use in neonates, infants, and children up to and including 15 years of age. The 20 mg dose of HBV vaccine was intended for use in subjects 16 years of age and older.…”

Section: Immunization Strategies For Children and High Risk Populatiomentioning

confidence: 99%

Strategy vaccination against Hepatitis B in China

Liao

Liang²

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Hepatitis B (HB) is a serious public health problem in China. Up to now, the hepatitis B virus (HBV) vaccination was the most cost-effective way to prevent HBV infection. Since 1992, when the Chinese government prioritized implementing the HBV vaccinations for newborns, China began to see a larger reduction in HBV infections. For children under 5 years, the prevalence of hepatitis B surface antigen (HBsAg) has decreased to 1.0%. However, many additional challenges for the prevention and control of HBV infection in China remain. There is a lack of knowledge of the significant impact of the HBV vaccination for the general public with 93 million HBV carriers and chronic HBV patients as infection sources. Therefore, the HBV vaccine application should focus on the optimization of immunization strategies according to HBV prevalence characteristics, improve the public's knowledge of HBV vaccinations, and help to ensure the protective effects of the HBV vaccine.

show abstract

“…The antibody response to HB vaccine has been found occurring in more than 90% of the healthy vaccinees [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15] . Kinetic studies showed serum anti-HBs levels decreased with time following vaccination [5,9,14,16] .…”

Section: Introductionmentioning

confidence: 99%

Long term persistence of T cell memory to HBsAg after hepatitis B vaccination

Wang¹,

Boland²,

Hattum³

et al. 2004

WJG

View full text Add to dashboard Cite

AIM:To determine if the T cell memory to HBsAg can persist for a long time after hepatitis B (HB) vaccination. METHODS:Thirty one vaccine recipients who were healthcare workers (18 females and 13 males aged 34-58 years) from Utrecht University Hospital, Netherlands, and had previously received a standard course of vaccination for hepatitis B were investigated and another 9 unvaccinated healthy volunteers from the same hospital were used as the control. Blood samples were taken just before the experiment to test serum anti-HBs levels and the subjects were classified into different groups according to their serum titers of antiHBs and vaccination history. Their peripheral blood mononuclear cells (PBMC) were isolated from freshly heparinized venous blood and the proliferative response of T lymphocytes to the recombinant hepatitis B surface antigen (HBsAg) was investigated. RESULTS:Positive serum anti-HBs was found in 61.3% (19/31) vaccine recipients and a significant in vitro lymphocyte proliferative response to recombinant HBsAg was observed in all the vaccinees with positive anti-HBs. Serum anti-HBs level 10 IU/L was found in 38.7% (12/31) subjects. In this study, we specially focused on lymphocyte proliferative response to recombinant HBsAg in those vaccine recipients with serum anti-HBsAg less than 10 IU/L. Most of them had received a standard course of vaccination about 10 years before. T lymphocyte proliferative response was found positive in 7 of the 12 vaccine recipients. These results confirmed that HBsAg-specific memory T cells remained detectable in the circulation for a long time after vaccination, even when serum anti-HBs level had been undetectable. CONCLUSION:The T cell memory to HBsAg can persist for at least 10 years after HB vaccination. Further booster injection is not necessary in healthy responders to HB vaccine.Wang RX, Boland GJ, van Hattum J, de Gast GC. Long term persistence of T cell memory to HBsAg after hepatitis B vaccination.

show abstract

Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience

Cited by 98 publications

References 31 publications

The response of hepatitis B vaccination on seronegative adults with different vaccination schedules

The response of hepatitis B vaccination on seronegative adults with different vaccination schedules

Strategy vaccination against Hepatitis B in China

Long term persistence of T cell memory to HBsAg after hepatitis B vaccination

Contact Info

Product

Resources

About